New designer benzodiazepines use in Barcelona

S. Pérez¹, M. de Dios¹, M. Grifell^{1,2}, L. Galindo^{1,2,4}, E. Monteagudo¹, A. Trabsa¹, D. Sanagustín¹, P. Quintana³, A. Palma^{1,2}, M. Ventura³, I. Fornís³, M. Farré^{4,5}, M. Torrens^{1,2,4}

¹ Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Barcelona, Spain.
² Institut Hospital del Mar d'Investigacions Mèdiques- IMIM, Parc de Salut Mar, Barcelona, Spain.
³ Energy Control, Asociación Bienestar y Desarrollo, Barcelona, Spain.
⁴ Universitat Autònoma de Barcelona, Bellaterra, Spain.
⁵ Servei de Farmacología Clínica, Hospital Universitari Germans Trias i Pujol, IGTP, Badalona, Spain.

Introduction

New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that they provide an attractive alternative to prescription-only benzodiazepines as they are readily available over the Internet at a low price.

Objective


To describe the presence of new designer benzodiazepines in samples delivered to Energy Control since 2010 to 2016 in Barcelona.

Methods

From 2010 to 2016, 24551 samples were delivered to EC. Among this samples 43 (0.175%) were analysed as BDZ. They were analyzed by Energy Control, a Spanish harm reduction NGO that offers the possibility of analyzing the substances that users report. Analysis was done by Gas Chromatography-Mass Spectrometry.

Results

From the 43 samples analyzed as benzodiazepines, 1 (2.32%) was delivered in 2010, none in 2011, 2 (4.65%) in 2012, 2 (4.65%) in 2013, 1 (2.32%) in 2014, 15 (34.88%) in 2015 and 21 (48.83%) in 2016.



Discussion

The data shows that new designer benzodiazepines use is increasing in Barcelona, specially in the last two years. Abuse an addiction to this drugs may be, in the future, a new public health problem in Barcelona. At the moment it has a small impact according to the result of our samples. A more precise monitoring would make a better approach to the real consumption and the impact of these substances in our society. Uncknown side effects may appear due to lack of information about pharmacokinethic profile of these drugs.

Bibliography

- 1- Hoiseth G, Tuv SS, Karinen R. Blood concentrations of new designer benzodiazepines in forensic cases. Forensic Sci Int. (2016) 268:35-38.
- 2- Corkery JM, Schifano F, Ghodse AH. Phenazepam abuse in the UK: an emerging problem causing serious adverse health problems, including death. Hum Psychopharmacol. (2012) 27(3):254-61.
- 3- Lukasik-Glebocka M, Sommerfeld K, Tezyk A, Zielinska-Psuia B, Panienski P, Zaba C. Flubromazolam: A new life-threatening designer benzodiazepine. Clin Toxicol (Phla). (2016) 54(1):66-8.

Acknowledgements

*No conflict of interests reported. Supported in part by grants of Instituto de Salud Carlos III-FEDER (RTA RD16/0017/0003 and RD16/0017/0010), L. Galindo is a Rio Hortega fellowship (ISC-III; CM14/00111).









